Tekmira Pharmaceuticals Corporation, together with collaborators at The University of Texas Medical Branch, has received a $2.4 million worth grant from National Institutes of Health to support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever viral infections using Tekmira's lipid nanoparticle delivery technology.
Tekmira Pharmaceuticals receives $2.4 million grant from National Institutes of Health